Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $39.73M (cash outflow) fell 11.0% year over year, behind the +7.6% change in trailing-twelve-month net income. Sequentially, it rose 5.1% from the prior quarter. Over 3 fiscal years it compounded at +77.4% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$127.05M (-21.2%) for the fiscal year ending Dec 2026, a slowdown from the +26.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.73M+5.1% QoQ
- Last fiscal yearDec 2025
- -$161.31M+26.5% YoY
- LTMMar 2026
- -$156.4M+7.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -11.0% | -2.6% | +8.4 pp |
| 1 year | +26.5% | -21.2% | -47.8 pp |
| 3-year CAGR | +77.4% | -14.5% | -91.9 pp |
| 5-year CAGR | -21.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (161.31M) USD
- Year-over-year change
- -26.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (161.31M) | -26.5% |
| FY2024 | 2024-12-31 | (127.48M) | -111.2% |
| FY2023 | 2023-12-31 | (60.37M) | -108.9% |
| FY2022 | 2022-12-31 | (28.89M) | -9.7% |
| FY2021 | 2021-12-31 | (26.35M) | — |
Net Income vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's LTM Mar 2026 net income of $156.4M is the 6th largest of the 11 companies compared; the peer median is $157.48M.
- Its year-over-year change of +7.6% is the 5th highest of 10, against a peer median of -19.9%.
- Over three fiscal years its annual growth of +77.4% compares with a peer median of +16.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $80.71B | +146477.0% | +53.5% | — | |
| LTM Mar 2026 | $246.41M | -26.3% | +14.4% | 794858.1% | |
| LTM Mar 2026 | $175.43M | +38.4% | +46.9% | — | |
| LTM Mar 2026 | $173.76M | -31.1% | -16.9% | — | |
| LTM Mar 2026 | $169.52M | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $156.4M | +7.6% | +77.4% | — | |
| LTM Mar 2026 | $145.44M | — | +20.7% | 15782.6% | |
| LTM Mar 2026 | $108.95M | -56.6% | -10.1% | 281.6% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $87.5M | -19.9% | +19.0% | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $58.44M | +17.3% | +35.2% | — |
| LTM Mar 2026 | $35.71M | -24.3% | -0.3% | 7142.0% | |
| Peer median (excluding KYTX) | $157.48M | -19.9% | +16.7% | 11462.3% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.25M | 929K | 2.22M | 8.36M | 10.08M |
| Change in Working Capital | (4.49M) | (10.33M) | 3.42M | 7.86M | (1.08M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 11K | 677K | 4.08M | 736K | 543K |
| Other Working Capital | (4.5M) | (11M) | (659K) | 7.12M | (1.62M) |
| Other Non-Cash Items | 850K | 1.13M | 605K | (5.12M) | (3.21M) |
| Operating Cash Flow | (22.16M) | (36.11M) | (52.41M) | (114.25M) | (153.71M) |
| Capital Expenditures | (1.29M) | (768K) | (621K) | (2.21M) | (5K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 70K |
| Purchases of Investments | 0 | (56.5M) | (54.85M) | (490M) | (364.62M) |
| Sales of Investments | 0 | 43.17M | 46.68M | 323.64M | 398.81M |
| Other Investing Activities | 0 | 0 | 0 | 7.66M | 5.76M |
| Investing Cash Flow | (1.29M) | (14.1M) | (8.79M) | (160.9M) | 40.02M |
| Debt Repayment | (41K) | (249K) | (781K) | (956K) | 23.89M |
| Common Stock Issued | 0 | 0 | 0 | 341.17M | 117.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 30K | 175K | (1M) | (3.1M) | (144K) |
| Financing Cash Flow | 72.52M | 11.88M | 58.12M | 337.11M | 141.17M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 49.08M | (38.33M) | (3.08M) | 61.96M | 27.47M |
| Free Cash Flow | (23.44M) | (36.88M) | (53.03M) | (116.46M) | (153.72M) |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.